Skip to main content

Table 4 Association between hormone receptor status of first breast cancer and subtype-specific contralateral breast cancer

From: Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

  ER+/PR+ CBC ER+/PR- CBC ER-/PR- CBC
Tumor status at first diagnosis N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI)
ER status
 Positive 365/421 1.0 (ref.) 123/147 1.0 (ref.) 89/241 1.0 (ref.)
 Negative 95/182 0.6 (0.4, 0.9) 55/67 0.9 (0.5, 1.6) 187/112 3.9 (2.4, 6.5)
 Other/unknownb 74/80   16/42   31/55  
PR status
 Positive 321/386 1.0 (ref.) 109/130 1.0 (ref.) 81/214 1.0 (ref.)
 Negative 106/184 0.8 (0.6, 1.1) 52/63 0.9 (0.5, 1.5) 183/115 3.8 (2.3, 6.3)
 Other/unknownb 107/113   33/63   43/79  
Joint ER/PR status
 ER+/PR+ 307/343 1.0 (ref.) 97/112 1.0 (ref.) 64/193 1.0 (ref.)
 ER+/PR- 30/50 0.7 (0.4, 1.2) 14/15 1.2 (0.5, 2.7) 20/28 2.6 (1.1, 5.7)
 ER-/PR- 74/130 0.7 (0.5, 1.0) 38/48 0.8 (0.4, 1.5) 162/83 5.4 (3.0, 9.5)
 Other/unknownb,c 123/160   45/81   61/104  
  1. Abbreviations: CBC contralateral breast cancer, RR risk ratio, CI confidence interval, N number, ER estrogen receptor, PR progesterone receptor
  2. aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, menopausal status, age at menarche, parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. b“Other/unknown” category consists of women for whom no laboratory test was given, the test was given and the results are unknown or the test was given and the results were borderline; estimates not reported. cIncludes tumors classified as ER-/PR+